The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.
Abstract
After a pause of nearly 40 years in research into the effects of psychedelic drugs, recent advances in our understanding of the neurobiology of psychedelics, such as lysergic acid diethylamide (LSD), psilocybin and ketamine have led to renewed interest in the clinical potential of psychedelics in the treatment of various psychiatric disorders. Recent behavioural and neuroimaging data show that psychedelics modulate neural circuits that have been implicated in mood and affective disorders, and can reduce the clinical symptoms of these disorders. These findings raise the possibility that research into psychedelics might identify novel therapeutic mechanisms and approaches that are based on glutamate-driven neuroplasticity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been suggested that the persisting therapeutic effects of psychedelics are attributable to a similar biological mechanism (39, 40).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [39]
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 1×
“5 mg per kg), and this effect was sustained for at least 72 hour”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 1×
“Dissociative anaesthetics mimic the positive and the negative symptoms (social withdrawal and apathy) of schizophrenia through antagonism at NMDA ( N -methyl- D -aspartate) glutamate receptor”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 1×
“Systemic administration of non-competitive NMDA antagonists, such as ketamine, PCP and MK-801 (also known as dizocilpine), in rats markedly increases glutamate release in the mPF”
BackgroundDavis, H. S. (1966) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1966.03100200106038 · Cited by 1,719
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 1×
“and was rated as among the most personally meaningful experience”
Background(1990) · Springer eBooks · doi:10.1007/978-3-642-74034-3 · Cited by 1,523
Anis, N. A., Berry, S. C., Burton, N. R., & Lodge, D. (1983) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1983.tb11031.x · Cited by 1,399
(2009) · Elsevier eBooks · doi:10.1016/c2009-1-03742-3 · Cited by 1,308
Homayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231 · cited 1×
“These effects are probably due to a blockade of NMDA receptors on GABA (γ-aminobutyric acid)-ergic interneuron”
Background
Research works printed but not linked: 6
- Hofmann, A. in Chemical Constitution and Pharmacodynamic Actions (ed. Burger, A.) 169–235 (M.Dekker, New York, 1968).
- Dittrich, A. in 50 Years of LSD. Current Status and Perspectives of Hallucinogens (eds Pletscher, A. & Ladewig, D.) 101–118 (Parthenon, New York, 1994).
- Hoffer, A. in The Uses and Implications of Hallucinogenic Drugs (eds Aaronson, B. & Osmond, H.) 357–366 (Hogarth Press, London, 1970).
- Leuner, H. in 50 Years of LSD: Current Status and Perspectives of Hallucinogen Research (eds Pletscher, A. & Ladewig, D.) 175–189 (Parthenon, New York, 1994).
- Crocket, R., Sandison, R. A. & Walk, A. in Proc. R. Med–Psychol. Assoc. (Lewis & Co., London, 1963).
- Leuner H. in Ethnopsychotherapie (eds Dittrich, A. & Scharfetter, C.) 151–161 (Enke, Stuttgard, 1987)
Cited by
Items 101–200 of 721
Shalit, N., Rehm, J., & Lev-Ran, S. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.09.020 · Cited by 129
Abraham, A. (2016) · Human Brain Mapping · doi:10.1002/hbm.23300 · Cited by 159
“Brain networks that orchestrate dissimilar functions become undifferentiated under such conditions leading to disorganized brain states and unconstrained cognition [Carhart-Harris et al., 2014; Gallimore, 2015; Tagliazucchi et al., 2014; Vollenweider and Kometer, 2010].”
BackgroundAcute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects
Mueller, F., Lenz, C., Dolder, P. C., Harder, S., Schmid, Y., Lang, U. E., Liechti, M. E., & Borgwardt, S. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.54 · Cited by 127
Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression
Ling, S., Ceban, F., Lui, L. M. W., Lee, Y., Teopiz, K. M., Rodrigues, N. B., Lipsitz, O., Gill, H., Subramaniapillai, M., Mansur, R. B., et al. (2022) · CNS Drugs · doi:10.1007/s40263-021-00877-y · Cited by 127
“In addition, re-expression of 5-HT2ARs in cortical pyramidal neurons was able to successfully restore hallucinogen-induced head twitching [44, 45].”
BackgroundOf Roots and Fruits: A Comparison of Psychedelic and Nonpsychedelic Mystical Experiences
Yaden, D. B., Le Nguyen, K. D., Kern, M. L., Belser, A. B., Eichstaedt, J. C., Iwry, J., Smith, M. E., Wintering, N. A., Hood, R. W., & Newberg, A. B. (2017) · Journal of Humanistic Psychology · doi:10.1177/0022167816674625 · Cited by 126
“Perhaps due to activity in the serotonergic system, psychedelics may also have antidepressant effects (Vollenweider & Kometer, 2010) and may be useful in the treatment of clinical depression (Anderson, 2012).”
BackgroundMotives and Side-Effects of Microdosing With Psychedelics Among Users
Hutten, N. R. P. W., Mason, N. L., Dolder, P. C., & Kuypers, K. P. C. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz029 · Cited by 126
dos Santos, R. G., Balthazar, F. M., Bouso, J. C., & Hallak, J. E. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116652578 · Cited by 125
Bogenschutz, M. P., & Pommy, J. M. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1376 · Cited by 125
“are thought to be due primarily to their actions at 5HT2A receptors.([1,32]) Stimulation of 5HT2A receptors causes activation of pyramidal cells in cerebral cortex.”
BackgroundTherapeutic infusions of ketamine: do the psychoactive effects matter?
Dakwar, E., Anerella, C., Hart, C. L., Levin, F. R., Mathew, S. J., & Nunes, E. V. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.12.019 · Cited by 123
“The approach of KPT, as of other therapies aimed at the pharmacological production of a transformative experience, is predicated on two notions: that the quality of the experience is crucial to efficacy, and that efficacy is enhanced by patient preparation and the treatment context (Hoffer, 1970; Johnson et al., 2008;…”
BackgroundHutten, N. R. P. W., Mason, N. L., Dolder, P. C., Theunissen, E. L., Holze, F., Liechti, M. E., Feilding, A., Ramaekers, J. G., & Kuypers, K. P. C. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.10.002 · Cited by 123
Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments
Schmidt, A., Bachmann, R., Kometer, M., Csomor, P. A., Stephan, K. E., Seifritz, E., & Vollenweider, F. X. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.261 · Cited by 121
“The specific doses were chosen based on previous studies (Kometer et al, 2011; Vollenweider and Kometer, 2010).”
MethodReiche, S., Hermle, L., Gutwinski, S., Jungaberle, H., Gasser, P., & Majić, T. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.09.012 · Cited by 122
“Moreover, psychedelics share a common mechanism of action at different 5-HT receptors, primarily the 5-HT2A receptor (Geyer and Vollenweider, 2008), which appears to be crucial for the specific psycho-vegetative effects, probably by activating a complex signal cascade (Halberstadt, 2015; Vollenweider and Kometer, 2010…”
BackgroundClassical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles
Baumeister, D., Barnes, G., Giaroli, G., & Tracy, D. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314527985 · Cited by 121
“Based on this finding, Vollenweider and Kometer have suggested that the indirect activation of glutamate networks by classical hallucinogens enhances neuroplasticity, specifically so via the AMPA (α-amino-3-hydroxyl-5-methyl4-isoxazole-propionic acid) receptor, with subsequent downstream increases in the cellular prot…”
BackgroundInfluentialEffects of hallucinogenic agents mescaline and phencyclidine on zebrafish behavior and physiology
Kyzar, E. J., Collins, C., Gaikwad, S., Green, J., Roth, A., Monnig, L., El-Ounsi, M., Davis, A., Freeman, A., Capezio, N., et al. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.01.003 · Cited by 120
Serotonergic Hallucinogen-Induced Visual Perceptual Alterations
Kometer, M., & Vollenweider, F. X. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_461 · Cited by 138
“The strong link between hallucinogens-induced visual percepts, emotions, and autobiographic memory has further been exploited in psycholytic or psychedelic therapy in western society (Leuner 1967; Grof 1973; Grinspoon and Bakalar 1986; Vollenweider and Kometer 2010; Carhart-Harris et al. 2012).”
BackgroundInfluentialSelf-citationClassic Psychedelic Drugs: Update on Biological Mechanisms
Vollenweider, F. X., & Smallridge, J. W. (2022) · Pharmacopsychiatry · doi:10.1055/a-1721-2914 · Cited by 128
“However, in the early 1990s, human psychedelic research with psilocybin, mescaline, and DMT resumed in healthy volunteers by employing different new brain imaging techniques and concepts borrowed from cognitive neurosciences [14].”
Self-citationBarrett, F. S., Carbonaro, T. M., Hurwitz, E., Johnson, M. W., & Griffiths, R. R. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4981-x · Cited by 109
Galvão, A. C. D. M., de Almeida, R. N., Silva, E. A. D. S., Freire, F. A. M., Palhano-Fontes, F., Onias, H., Arcoverde, E., Maia-de-Oliveira, J. P., de Araújo, D. B., Lobão-Soares, B., et al. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00185 · Cited by 108
Altered States of Consciousness
Presti, D. E. (2017) · Wiley eBooks · doi:10.1002/9781119132363.ch12 · Cited by 113
Kraehenmann, R., Schmidt, A., Friston, K., Preller, K. H., Seifritz, E., & Vollenweider, F. X. (2016) · NeuroImage: Clinical · doi:10.1016/j.nicl.2015.08.009 · Cited by 104
“This mechanism may crucially underlie the previously observed decrease of behavioral and electrophysiological responses in the visual cortex to threat stimuli during psilocybin administration (Vollenweider and Kometer, 2010; Schmidt et al., 2013a) and may explain the psilocybininduced shifts away from negative towards…”
Self-citationClassical hallucinogens and neuroimaging: A systematic review of human studies
dos Santos, R. G., Osório, F. L., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.10.026 · Cited by 107
“…neurons rich in 5-HT2A receptors seem to be the main mechanism of action of these compounds (Vollenweider et al., 1998; Hintzen and Passie, 2010; Vollenweider and Kometer, 2010; Kometer et al., 2012, 2013; Hanks and González-Maeso, 2013; Baumeister et al., 2014; Tylš et al., 2014; Halberstadt,…”
Dakwar, E., Hart, C. L., Levin, F. R., Nunes, E. V., & Foltin, R. W. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.39 · Cited by 105
A Dendrite-Focused Framework for Understanding the Actions of Ketamine and Psychedelics
Savalia, N. K., Shao, L.-X., & Kwan, A. C. (2021) · Trends in Neurosciences · doi:10.1016/j.tins.2020.11.008 · Cited by 104
“We are not the first to note the comparable effects of serotonergic psychedelics and ketamine in terms of neural and behavioral consequences [20,21].”
BackgroundLindholm, J., Autio, H., Vesa, L., Antila, H., Lindemann, L., Hoener, M. C., Skolnick, P., Rantamäki, T., & Ċastrén, E. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.015 · Cited by 112
“Drugs targeting brain glutamatergic signaling pathways are recognized as potential antidepressant drug candidates (Alt et al., 2006; Skolnick et al., 2009; Vollenweider and Kometer, 2010).”
BackgroundTwo dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow
Lewis, C. R., Preller, K. H., Kraehenmann, R., Michels, L., Staempfli, P., & Vollenweider, F. X. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.07.020 · Cited by 102
“, 2016) all differed from placebo (Vollenweider and Kometer, 2010; Griffiths et al., 2011).”
InfluentialSelf-citationBehavioral Neurobiology of Psychedelic Drugs
(2018) · Current topics in behavioral neurosciences · doi:10.1007/978-3-662-55880-5 · Cited by 118
Therapeutic use of psilocybin: Practical considerations for dosing and administration
MacCallum, C. A., Lo, L. A., Pistawka, C. A., & Deol, J. K. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1040217 · Cited by 102
Serotonergic psychedelics temporarily modify information transfer in humans.
Alonso, J. F., Romero, S., Mañanas, M. À., & Riba, J. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv039 · Cited by 101
“Evidence of their modulatory capacity on the amygdala and ACC suggests their potential efficacy in the treatment of affective disorders (Vollenweider and Kometer, 2010; Kraehenmann et al., 2014).”
5-HT and depression: is the glass half-full?
Sharp, T., & Cowen, P. J. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.02.003 · Cited by 153
Kadriu, B., Greenwald, M., Henter, I. D., Gilbert, J. R., Kraus, C., Park, L. T., & Zarate, C. A. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa087 · Cited by 99
“In terms of immediate drug effects, both ketamine and SPs appear to trigger a “glutamate surge” (Razoux et al., 2007; Vollenweider and Kometer, 2010).”
BackgroundPsilocybin for treating substance use disorders?
de Veen, B. T. H., Schellekens, A. F. A., Verheij, M. M. M., & Homberg, J. R. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1220834 · Cited by 99
“below) and pharmacological properties, human experimental research on the neuropsychological effects of psilocybin has revived since the late 1990s (for review [40,41]).”
BackgroundMathai, D. S., Meyer, M. J., Storch, E. A., & Kosten, T. R. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.12.023 · Cited by 97
Bouso, J. C., Fábregas, J. M., Antonijoan, R. M., Rodríguez-Fornells, A., & Riba, J. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3167-9 · Cited by 96
“Because of the profound impact of psychedelics on thought processes, their recently uncovered capacity to stimulate intrinsic activity within the prefrontal cortex and the similarities between the subjective effects they induce and endogenous psychoses (Béïque et al. 2007; Geyer and Vollenweider 2008; GouzoulisMayfran…”
Varley, T. F., Carhart-Harris, R., Roseman, L., Menon, D. K., & Stamatakis, E. A. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.117049 · Cited by 96
The acute effects of classic psychedelics on memory in humans
Healy, C. J. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05756-w · Cited by 106
Dose–response relationships of psilocybin-induced subjective experiences in humans
Hirschfeld, T., & Schmidt, T. T. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881121992676 · Cited by 93
“Previous work also suggests a linear relationship of subjective experiences for medium to high doses of psilocybin is a good fitting model (Vollenweider and Kometer, 2010; Studerus et al., 2011).”
BackgroundMethodPharmacology of Hallucinations: Several Mechanisms for One Single Symptom?
Rolland, B., Jardri, R., Amad, A., Thomas, P., Cottencin, O., & Bordet, R. (2014) · BioMed Research International · doi:10.1155/2014/307106 · Cited by 112
“Although there has been much debate regarding the psychedelics’ exact pharmacological mechanism [29], the most commonly admitted mode of activity of this class of drugs is the stimulation of serotonin 5HT2AR on cortical neurons [30, 31].”
BackgroundDreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications
Kraehenmann, R. (2017) · Current Neuropharmacology · doi:10.2174/1573413713666170619092629 · Cited by 92
“classic psychedelics produce their effects primarily via activation of postsynaptic cortical serotonin 2A (5HT2A) receptors on pyramidal neurons in layer V of the prefrontal cortex (PFC), leading to glutamate-dependent downstream activity changes [85]; 2.”
BackgroundGregorio, D. D., Enns, J. P., Núñez, N. A., Posa, L., & Gobbi, G. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.07.008 · Cited by 103
A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers
Ramaekers, J. G., Hutten, N., Mason, N. L., Dolder, P., Theunissen, E. L., Holze, F., Liechti, M. E., Feilding, A., & Kuypers, K. P. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120940937 · Cited by 92
“LSD may also possess therapeutic properties (Liechti, 2017; Vollenweider and Kometer, 2010) and has been implicated in the management of pain (Whelan and Johnson, 2018).”
Brennan, W., & Belser, A. B. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.866018 · Cited by 90
Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination
Grimm, O., Kraehenmann, R., Preller, K. H., Seifritz, E., & Vollenweider, F. X. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.03.016 · Cited by 90
Self-citationAmidfar, M., Woelfer, M., Réus, G. Z., Quevedo, J., Walter, M., & Kim, Y.-K. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109668 · Cited by 90
Grimm, O., Gass, N., Weber‐Fahr, W., Sartorius, A., Schenker, E., Spedding, M., Risterucci, C., Schweiger, J. I., Böhringer, A., Zang, Z., et al. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4022-y · Cited by 106
“From a psychopathological perspective, ketamine captures psychosis only broadly, but when looking at the exact changes in mind states (Vollenweider and Kometer 2010), it certainly does not mirror symptoms seen in schizophrenia.”
BackgroundHigh doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens
Reissig, C. J., Carter, L. P., Johnson, M. W., Mintzer, M. Z., Klinedinst, M. A., & Griffiths, R. R. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2680-6 · Cited by 89
“Reviewing recent data , Vollenweider and Kometer ( 2010 ) proposed that the classic hallucinogens increase glutamate levels in the prefrontal cortex via 5 - HT2A receptors localized on pyramidal cells in the cortex .”
Schmidt, A., Kometer, M., Bachmann, R. F., Seifritz, E., & Vollenweider, F. X. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2811-0 · Cited by 102
“Furthermore, given the putative therapeutic potential of psilocybin (Kometer et al. 2012; Vollenweider and Kometer 2010; Grob et al. 2011), an oral dosing regimen provides a more personable setup than utilizing an intravenous dosing regime for psilocybin.”
BackgroundSelf-citationMeinhardt, M. W., Pfarr, S., Fouquet, G., Rohleder, C., Meinhardt, M. L., Barroso-Flores, J., Hoffmann, R., Jeanblanc, J., Paul, E., Wagner, K., et al. (2021) · Science Advances · doi:10.1126/sciadv.abh2399 · Cited by 89
Drugs and Drug Policy: What Everyone Needs To Know®
R.Kleiman, M. A., Caulkins, J. P., & Hawken, A. (2011) · doi:10.1093/wentk/9780199764518.001.0001 · Cited by 133
Hendricks, P. S., Clark, C. B., Johnson, M. W., Fontaine, K. R., & Cropsey, K. L. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113513851 · Cited by 88
“…are a class of psychoactive substances with low dependence potential that produce mystical-type experiences characterized by pseudo-hallucinations and feelings of bliss, unity, and transcendence of time and space (Griffiths et al., 2006; Johnson et al., 2008; Vollenweider and Kometer, 2010).”
BackgroundInfluentialAcute psilocybin enhances cognitive flexibility in rats
Torrado Pacheco, A., Olson, R. J., Garza, G., & Moghaddam, B. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01545-z · Cited by 87
“Studies with psilocin and related compounds such as lysergic acid diethylamide (LSD) suggest that psilocybin decreases DRN firing [56, 58, 65, 66], which may play a role in modulating behavioral flexibility.”
Mason, N. L., Szabó, A., Kuypers, K. P. C., Mallaroni, P., de la Torre, R., Reckweg, J. T., Tse, D. H. Y., Hutten, N. R. P. W., Feilding, A., & Ramaekers, J. G. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.09.004 · Cited by 102
“…have been found to be altered by psychedelic drugs and suggested to play a role in the therapeutic efficacy of these substances in clinical trials (Mason et al., 2020; Vollenweider and Kometer, 2010; Doss et al., 2021; Sampedro et al., 20172017; Nichols and Barker, 2016; van Elk and Yaden, 2022).”
The impact of Ayahuasca on suicidality: results from a randomized controlled trial
Zeifman, R. J., Palhano-Fontes, F., Hallak, J., Arcoverde, E., Maia-Oliveira, J. P., & Araujo, D. B. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01325 · Cited by 87
“, 2018), and markers of neuroplasticity (Nichols and Sanders-Bush, 2002), within the prefrontal cortex, a region of the brain implicated in emotion dysregulation (Vollenweider and Kometer, 2010) and suicidality (Ding et al.”
BackgroundPsychedelics and music: neuroscience and therapeutic implications
Barrett, F. S., Preller, K. H., & Kaelen, M. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1484342 · Cited by 86
“LSD-induced enhancement of autobiographical memories, and associated with this the potential reversal of negative cognitive biases, might be associated with beneficial therapy outcome (Carhart-Harris et al., 2012b; Kraehenmann et al., 2015; Vollenweider & Kometer, 2010).”
BackgroundHeuschkel, K., & Kuypers, K. P. C. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00224 · Cited by 86
Guss, J., Krause, R., & Sloshower, J. (2020) · doi:10.31234/osf.io/u6v9y · Cited by 86
Dakwar, E., Nunes, E. V., Hart, C. L., Hu, M. C., Foltin, R. W., & Levin, F. R. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.005 · Cited by 85
“Neurobiological mechanisms common to agents eliciting mystical-type phenomena, and which may also be involved in psychiatric efficacy, include the promotion of prefrontal neurogenesis, alterations in default-mode network (DMN) connectivity, and increased synchrony between the anti-correlated networks (Carhart-Harris e…”
Therapeutic Applications of Classic Hallucinogens
Bogenschutz, M. P., & Ross, S. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_464 · Cited by 109
Oral ketamine for the treatment of pain and treatment-resistant depression
Schoevers, R. A., Chaves, T. V., Balukova, S. M., Rot, M. A. H., & Kortekaas, R. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.115.165498 · Cited by 81
Repeated low doses of LSD in healthy adults: A placebo‐controlled, dose–response study
de Wit, H., Molla, H. M., Bershad, A. K., Bremmer, M. P., & Lee, R. (2022) · Addiction Biology · doi:10.1111/adb.13143 · Cited by 93
Brandt, S. D., Kavanagh, P. V., Westphal, F., Stratford, A., Elliott, S. P., Hoang, K., Wallach, J. V., & Halberstadt, A. L. (2015) · Drug Testing and Analysis · doi:10.1002/dta.1884 · Cited by 84
Ketamine administration reduces amygdalo‐hippocampal reactivity to emotional stimulation
Scheidegger, M., Henning, A., Walter, M., Lehmann, M., Kraehenmann, R., Boeker, H., Seifritz, E., & Grimm, S. (2016) · Human Brain Mapping · doi:10.1002/hbm.23148 · Cited by 79
“positively experienced loss of ego boundaries that are associated with changes in the sense of time and emotions) and “visionary restructuralization” (referring to altered meaning of percepts) raises interesting new hypotheses regarding the therapeutic mechanisms of psychedelics and their clinical applications [Vollen…”
BackgroundMethodDecreased directed functional connectivity in the psychedelic state
Barnett, L., Muthukumaraswamy, S. D., Carhart-Harris, R. L., & Seth, A. K. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2019.116462 · Cited by 78
Psilocybin and MDMA for the treatment of trauma-related psychopathology
Bird, C. I. V., Modlin, N. L., & Rucker, J. J. H. (2021) · International Review of Psychiatry · doi:10.1080/09540261.2021.1919062 · Cited by 80
“They are agonists at serotonin receptors, with the subjective psychoactive effects dependent on partial agonism of the type 2A serotonin receptor (Vollenweider & Kometer, 2010), which is predominantly expressed on layer V pyramidal neurons in the prefrontal cortex (Hall et al., 2000; Saulin et al.,…”
BackgroundAcute subjective effects in LSD- and MDMA-assisted psychotherapy
Schmid, Y., Gasser, P., Oehen, P., & Liechti, M. E. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959604 · Cited by 85
“The scale is well-validated and has been used to characterise the subjective effects of various psychedelic drugs (Hasler et al., 2004; Hysek et al., 2011; Liechti et al., 2017; Vollenweider and Kometer, 2010; Vollenweider et al., 2007; Schmid et al., 2015a; Studerus et al., 2010).”
BackgroundLara, D. R., Bisol, L. W., Brunstein, M. G., Reppold, C. T., de Carvalho, H. W., & Ottoni, G. L. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.08.036 · Cited by 87
“while they are present and also long-term effects due to rapidly induced structural changes in the brain (Li et al., 2010; Vollenweider and Kometer, 2010).”
BackgroundRomeo, B., Hermand, M., Pétillion, A., Karila, L., & Benyamina, A. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.03.002 · Cited by 76
“Several post-mortem studies show that depressive patients had a depletion of the cortical expression of 5-HT1A/2A/2C receptors, suggesting its potential role in emotional processing (Baumeister et al., 2014; Vollenweider and Kometer, 2010).”
BackgroundPsilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy
Dodd, S., Norman, T. R., Eyre, H. A., Stahl, S. M., Phillips, A., Carvalho, A. F., & Berk, M. (2023) · CNS Spectrums · doi:10.1017/s1092852922000888 · Cited by 73
“These neurochemical changes are accompanied by intracellular and downstream receptor alterations, which have been associated with a proposed mechanism of action of hallucinogens in general.(30) It is suggested that hallucinogenic 5HT2A agonists differentially activate cortical pyramidal neurons resulting in increased…”
Sumner, R. L., Chacko, E., McMillan, R., Spriggs, M. J., Anderson, C., Chen, J., French, A., Jung, S., Rajan, A., Malpas, G., et al. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881121998321 · Cited by 72
“…downstream glutamatergic action and the consequences for neural plasticity provide plausible shared mechanisms by which ketamine, LSD, psilocybin, ayahuasca, MDMA, and other psychedelic drugs may exert their therapeutic effects (Ly et al., 2018; Reiff et al., 2020; Vollenweider and Kometer, 2010).”
BackgroundInfluentialBuchborn, T., Schröder, H., Höllt, V., & Grecksch, G. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114531666 · Cited by 72
“…neuroses and/or depressive reactions (Mascher, 1967; Savage et al., 1973), the therapeutic potential of serotonergic hallucinogens has hardly been considered pharmacologically, i.e. in terms of their receptor profile (Montagne, 2007; Riedlinger and Riedlinger, 1994; Vollenweider and Kometer, 2010).”
BackgroundRiga, M. S., Soria, G., Tudela, R., Artigas, F., & Celada, P. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000261 · Cited by 72
Positive psychology in the investigation of psychedelics and entactogens: a critical review
Jungaberle, H., Thal, S., Zeuch, A., Rougemont-Bücking, A., von Heyden, M., Aicher, H., & Scheidegger, M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.06.034 · Cited by 70
Higgins, G. A., Carroll, N. K., Brown, M., MacMillan, C., Silenieks, L. B., Thevarkunnel, S., Izhakova, J., Magomedova, L., DeLannoy, I., & Sellers, E. M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.640241 · Cited by 69
“highlighted the overlapping psychotic syndromes produced by serotonergic hallucinogens and psychotomimetic anesthetics associated with a marked activation of the prefrontal cortex and other overlapping changes in temporoparietal, striatal, and thalamic regions (Vollenweider, 2001; Vollenweider and Kometer, 2010) sugge…”
BackgroundAlterations of Expression of the Serotonin 5-HT4 Receptor in Brain Disorders
Rebholz, H., Friedman, E., & Castelló, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113581 · Cited by 84
“5-HT2aR mediates the hallucinatory and psychotic action of psychedelic drugs such as LSD or psylocibin [5].”
BackgroundBettinardi, R. G., Tort-Colet, N., Ruiz-Mejias, M., Sanchez-Vives, M. V., & Deco, G. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2015.03.037 · Cited by 68
“, 2012), psychedelic states (Vollenweider and Kometer, 2010; Carhart-Harris et al., 2012, 2013), and also at”
BackgroundAust, S., Gärtner, M., Basso, L., Otte, C., Wingenfeld, K., Chae, W. R., Heuser-Collier, I., Regen, F., Cosma, N. C., van Hall, F., et al. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.02.005 · Cited by 67
Zeifman, R. J., & Wagner, A. C. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.11.001 · Cited by 67
Weiss, F., Magnesa, A., Gambini, M., Gurrieri, R., Annuzzi, E., Elefante, C., Perugi, G., & Marazziti, D. (2025) · Brain Sciences · doi:10.3390/brainsci15020117 · Cited by 74
“Furthermore, psychedelics, acting on 5-HT2A receptors located on pyramidal cells’ apical dendrites, increase glutamate-mediated neurotransmission through AMPA receptors [123].”
The epistemic innocence of psychedelic states
Letheby, C. (2016) · Consciousness and Cognition · doi:10.1016/j.concog.2015.11.012 · Cited by 67
Duerler, P., Brem, S., González, G. F., Neef, T., Allen, M., Zeidman, P., Stämpfli, P., Vollenweider, F. X., & Preller, K. H. (2021) · Cerebral Cortex · doi:10.1093/cercor/bhab202 · Cited by 73
“Scores were calculated for 11 validated second order scales (Studerus, Gamma, Vollenweider 2010): experience of unity, spiritual experience, blissful state, insightfulness, disembodiment, impaired control and cognition, anxiety, complex imagery, elementary imagery, audiovisual synesthesia, and…”
BackgroundMethodInfluentialSelf-citationBarnett, B. S., Beaussant, Y., King, F., & Doblin, R. (2021) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2021.1957183 · Cited by 71
“Though not yet as intensively investigated, ayahuasca, ibogaine, and lysergic acid diethylamide (LSD), have also shown treatment potential for substance use and psychiatric disorders (Begola and Schillerstrom 2019; Vollenweider and Kometer 2010).”
BackgroundXu, K., Krystal, J. H., Ning, Y., Chen, D. C., He, H., Wang, D., Ke, X., Zhang, X., Ding, Y., Liu, Y., et al. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.12.012 · Cited by 66
“For these reasons, the effects of NMDA receptor antagonists emerge as one of the central models for schizophrenia drug development (Coyle et al., 2002; Javitt, 2008; Nikiforuk et al., 2013; Vollenweider and Kometer, 2010).”
BackgroundMertens, L. J., & Preller, K. H. (2021) · Pharmacopsychiatry · doi:10.1055/a-1341-1907 · Cited by 65
“The scientific investigation of these substances was catalyzed by the discovery of the psychological effects of LSD in 1943 by Albert Hofmann [1].”
BackgroundMethodInfluentialA unified model of ketamine’s dissociative and psychedelic properties
Marguilho, M., Figueiredo, I., & Castro-Rodrigues, P. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221140011 · Cited by 76
“As Vollenweider and Kometer (2010) show, larger doses of ketamine produce ego dissolution experiences more frequently than lower doses (Vollenweider and Kometer, 2010), although to our knowledge the effect of dose increase in the same patient has never been formally tested.”
BackgroundMethodInfluentialWalsh, Z., Hendricks, P. S., Smith, S., Kosson, D. S., Thiessen, M. S., Lucas, P., & Swogger, M. T. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116642538 · Cited by 64
“However, the broad class of hallucinogens extends beyond these “classic psychedelics” to include substances with other primary modes of actions such as ketamine, phenylcyclidine (PCP), ibogaine, Salvia divinorum, and methylenedioxymethamphetamine (MDMA) (Bogenschutz and Pommy, 2012; Nichols, 2004; Vollenweider and Kom…”
BackgroundInfluentialEffects of ketamine on cognition–emotion interaction in the brain
Scheidegger, M., Henning, A., Walter, M., Boeker, H., Weigand, A., Seifritz, E., & Grimm, S. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2015.08.070 · Cited by 64
“Alternativeley, ketamine induces alterations in subjective state with symptoms of disembodiment, experience of unity and vivid imagery (Vollenweider and Kometer, 2010), resulting from a mismatch between interoceptive and exteroceptive information processing that could be reflected in diminished…”
BackgroundMethodInfluentialAcute Pharmacological Effects of 2C-B in Humans: An Observational Study
Papaseit, E., Farré, M., Pérez-Mañá, C., Torrens, M., Ventura, M., Pujadas, M., de la Torre, R., & González, D. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00206 · Cited by 59
“From a pharmacological point of view, preclinical studies have demonstrated that 2C-drugs inhibit the norepinephrine (NE) and serotonin transporters (NET and SERT, respectively) with very low potency in comparison to amphetamines (Glennon et al., 1984; Vollenweider and Kometer, 2010).”
BackgroundPsychedelic‐inspired approaches for treating neurodegenerative disorders
Saeger, H. N., & Olson, D. E. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15544 · Cited by 74
“…knockout (KO) of 5- HT2A receptors eliminates psychedelic- induced HTR in mice (González- Maeso et al., 2007),and blocking 5- HT2 receptors using ketanserin abolishes the subjective effects of both psilocybin (Vollenweider et al., 1998) and LSD (Holze et al., 2021; Preller et al., 2018) in humans.”
Hassan, Z., Bosch, O. G., Singh, D., Narayanan, S., Kasinather, B. V., Seifritz, E., Kornhuber, J., Quednow, B. B., & Müller, C. P. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00152 · Cited by 76
“However, all 5-HT hallucinogens have in common that they induce altered states of consciousness (186, 187).”
BackgroundGasull-Camós, J., Tarrés-Gatius, M., Artigas, F., & Castañé, A. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.7 · Cited by 62
The emerging role of psilocybin and MDMA in the treatment of mental illness
Gill, H., Gill, B., Chen-Li, D., El-Halabi, S., Rodrigues, N. B., Cha, D. S., Lipsitz, O., Lee, Y., Rosenblat, J. D., Majeed, A., et al. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1826931 · Cited by 61
Jones, G. M., & Nock, M. K. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211058923 · Cited by 68
“…receptors (the site through which antidepressants and antipsychotics potentiate their effects) (Mahapatra and Gupta, 2017; Van Oekelen et al., 2003; Vollenweider and Kometer, 2010), and reducing markers of inflammation that are linked to STBs and related mental health disorders (Flanagan and…”
BackgroundStewart, A., & Kalueff, A. V. (2013) · Brain Research · doi:10.1016/j.brainres.2013.11.002 · Cited by 70
DARK Classics in Chemical Neuroscience: NBOMes
Poulie, C. B. M., Jensen, A. A., Halberstadt, A. L., & Kristensen, J. L. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00528 · Cited by 61
Prognosis and Improved Outcomes in Major Depression: A Review
Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C. A., & Kasper, S. (2020) · Focus · doi:10.1176/appi.focus.18205 · Cited by 62
Smausz, R., Neill, J. C., & Gigg, J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221092508 · Cited by 70
“The main advocates of the hypothesis that psilocybin increases PFC activity are a Zürich-based group (Vollenweider and Kometer, 2010; Vollenweider and Preller, 2020).”
BackgroundInfluentialBernasconi, F., Schmidt, A., Pokorny, T., Kometer, M., Seifritz, E., & Vollenweider, F. X. (2014) · Cerebral Cortex · doi:10.1093/cercor/bht178 · Cited by 60
“For instance, it has been shown that the selective 5-HT1A/2A receptor agonist psilocybin modulates the neural activity within circuits related to emotion regulation (Nichols 2004; Vollenweider and Kometer 2010; Carhart-Harris, Erritzoe, et al. 2012; Carhart-Harris, Leech, et al. 2012).”
BackgroundSelf-citationNeuropharmacological modulation of the aberrant bodily self through psychedelics
Ho, J. T., Preller, K. H., & Lenggenhager, B. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.12.006 · Cited by 59
Mouse BOLD fMRI at ultrahigh field detects somatosensory networks including thalamic nuclei
Jung, W. B., Shim, H., & Kim, S. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.03.063 · Cited by 66
Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives
Pallavicini, C., Vilas, M. G., Villarreal, M., Zamberlan, F., Muthukumaraswamy, S., Nutt, D., Carhart-Harris, R., & Tagliazucchi, E. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.06.053 · Cited by 58
“Differences in the subjective effects elicited by low to moderate doses of ketamine and SP appear in the quality and intensity of sensory alterations, mainly in the visual domain (Vollenweider and Kometer, 2010).”
BackgroundPsilocybin for End-of-Life Anxiety Symptoms: A Systematic Review and Meta-Analysis
Yu, C., Yang, F., Yang, S., Tseng, P., Stubbs, B., Yeh, T., Hsu, C., Li, D., & Liang, C. (2021) · Psychiatry Investigation · doi:10.30773/pi.2021.0209 · Cited by 73
Metadata
- Authors
- Vollenweider, F. X., & Kometer, M.
- Affiliations
- University of Zurich (CH)
- University Hospital Zurich (CH)
- Corresponding author
- Vollenweider, Franz X.
- Venue
- Nature Reviews Neuroscience
- Published
- 2010-08-18
- Volume
- 11
- Issue
- 9
- Pages
- 642-651
- ISSN
- 1471-003X (ISSN-L)
- 1471-0048
- OpenAlex
- W2068751924
- Semantic Scholar
- d95a57f4b1e3288f21a7dab08ebc2fd5ff10a762
- Cited by
- 723
- References
- 149
- Citations by year
- 2026: 55 · 2025: 75 · 2024: 55 · 2023: 64 · 2022: 53 · 2021: 63 · 2020: 50 · 2019: 35 · 2018: 56 · 2017: 37 · 2016: 48 · 2015: 29 · 2014: 24 · 2013: 18 · 2012: 25
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- psychedelics, mood disorders, serotonergic system, glutamatergic system, dissociative anesthetics, LSD, psilocybin, ketamine, neuroplasticity, neural circuits, psychiatric treatment
- MeSH terms
- Animals, Brain, Hallucinogens, Humans, Models, Neurological, Mood Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.